Live feed06:45:00·1973dPRReleasevia QuantisnowLilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19ByQuantisnow·Wall Street's wire, on your screen.LLY· Eli Lilly and CompanyGSK· GSK plcVIR· Vir Biotechnology Inc.Health CareOriginal source
